ANGANY CEO Dr. Louis-Philippe Vézina is very pleased to announce the collaboration of world-renowned Pr. Durham and Pr. Shamji, authorities in the field of allergy, to the activities of its Scientific Advisory Board. Pr. Durham brings a unique wealth of knowledge and experience in the clinical development of allergy therapeutics. Pr. Shamji, Chair of the virtual EAACI Congress 2020, of the EAACI Scientific Program Committee and EAACI’s Immunotherapy Interest Group will provide invaluable insights as ANGANY proceeds with pre-clinical studies of its allergy candidate-therapeutics.